Compare UFG & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | CLGN |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 23.1M |
| IPO Year | 2025 | N/A |
| Metric | UFG | CLGN |
|---|---|---|
| Price | $0.99 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 273.6K | 21.4K |
| Earning Date | 10-28-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $195,620,824.00 | $2,475,000.00 |
| Revenue This Year | $41.40 | $1,617.28 |
| Revenue Next Year | $25.00 | $83.54 |
| P/E Ratio | $172.99 | ★ N/A |
| Revenue Growth | 49.71 | ★ 280.77 |
| 52 Week Low | $0.66 | $1.31 |
| 52 Week High | $11.00 | $4.98 |
| Indicator | UFG | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 31.73 |
| Support Level | $0.75 | $1.77 |
| Resistance Level | $1.15 | $1.93 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 66.57 | 0.00 |
Uni-Fuels Holdings Ltd is a service provider of marine fuels solutions. The company market, resell and brokers marine fuels products such as VLSFO, HSFO, and MGO. It offers these products to shipping companies and marine fuels suppliers in-port and offshore. In addition, the company may from time to time provide shipping-related services to its customers including but not limited to the arrangement of ship agents, ship provisions and marine fuels surveyors. It operates an integrated business model where It serves its customers through two operating models, sales of marine fuels solutions and brokerage.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.